offers a general, industry-wide approach to infertility treatment as a commercial enterprise. Important for Spar is the claim that treating infertility involves the "business" of buying babies, hence her title The Baby Business: How Money, Science, and Politics Drive the Commerce of Conception. A soft-focus profile of a partly shadowed baby's face on the jacket with a bar code under one eye cleverly suggests her theme of price and commercialization.
It quickly becomes apparent, however, that the term "business" is used so broadly that it adds fizz but little juice to understanding the practices she describes. She promises to tell us " [w] hat defines the boundary . . . that separate [s] commerce from things too valuable to sell," as well as "who gets to decide where this boundary lies, and what rules govern the most intimate of decisions."
5 But she never delivers the goods. Too much time is spent on journalistic description and sloganeering and too little on analysis to tell us anything new about how legal and policy issues in this "idiosyncratic trade" should be resolved.
The overall tone or attitude of the book is one of shock and awe that money is being paid to treat infertility. There is plangent hand-wringing that interstate commerce is being used by people trying to have babies and by those professionals who help them. She uses that trope to frame the discussion that follows. At the same time, she is quick to say that she is only describing the field for the purpose of better regulation. By the last chapter, she has pulled her punches altogether, reverting to a good business school mode of accepting the quasi-market system for allocating reproductive components and services that is now firmly in place. Yes, society can regulate it any way that it wants, but she offers no suggestions for how that should be done, nor, indeed, that there is a pressing need to do so at all. 6 Spar's account is not without virtues. Her book is spritely written, has engaging chapter and section titles, and covers journalistically a fair bit of history and recent events in the reproductive field. Newcomers to the field will have a pleasant read and learn something. Those moderately familiar with the area may also glean some grains of historical fact and the sequence of controversy. Those well-versed in reproductive issues would spend their time more fruitfully elsewhere.
Although Spar doesn't deliver the goods, her book does invite attention to the issues raised by the presence of money and markets in assisted reproductive services. Part I discusses Spar's account of reproductive technology. Part II describes the components of a market analysis that would shed light on the field. Part III then examines five ongoing areas of debate or Texas Law Review [Vol. 85:665 concern about money and the role of commercial or market factors in ART. Part IV concludes.
I. Spar's Account of the Reproductive Technology Industry
Spar's bait to readers is her claim that current infertility and adoption practices amount to a "baby trade" or "baby business" where "every day, in nearly every country, infants and children are indeed being sold" as part of standard infertility treatment.
7 This is troubling because
[a]s people-as parents-we don't like to think of children as economic objects. They are products, we insist, of love, not money; of an intimate creation that exists far beyond the reach of any market impulse. And yet, over the past thirty years, advances in reproductive medicine have indeed created a market for babies, a market in which parents choose traits, clinics woo clients, and specialized providers earn millions of dollars a year. In this market, moreover, commerce often runs without many rules. 8 . . . . The central argument of this book, therefore, is that despite popular protests to the contrary, and despite the heartfelt sentiments of parents and providers, there is a flourishing market for both children and their component parts. Eggs are being sold; sperm is being sold; wombs and genes and orphans are being sold; and many individuals are profiting handsomely in the process.
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Despite this horrified tone, Spar insists that she is only describing, not judging. We cannot know where and whether to regulate unless we understand who the baby-makers are and how they are structuring their trade. We need to examine who makes money in this industry and what defines the clientele. Harsh as it may seem, we need to view reproductive medicine as an industry, with all the commercial prospects and potential foibles that other industries display.
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Most of the book is descriptive of the many areas in which she claims that commerce in reproduction is occurring. Chapter 1 gives a history of human efforts to outwit the plague of infertility and the development of modern IVF. Chapter 2 describes market aspects, sperm banking, the sale of fertility drugs, and the development of a series of commercial IVF clinics. Chapter 3 then gives a history of surrogacy from the Baby M case 11 to more 7. SPAR, supra note 3, at x. 8. Id. at xi. Further, "This market, however, remains largely unacknowledged. No one likes to admit to manufacturing babies or to earning profits in the process. No one wants to argue that the baby business should be seen as commerce . . . ." Id. at xiv.
9. Id. at xv. 10. Id. 11. See In re Baby M, 537 A.2d 1227 (N.J. 1988) (invalidating a surrogacy contract as against public policy). recent developments. Chapter 4 deals with issues of design and selection, including a history of eugenics and an account of the emergence of preimplantation screening of embryos for genetic traits. Chapter 5 deals with the history and controversy over reproductive and therapeutic cloning. Chapter 6 deals with adoption and the growing international market for adoptive kids. In Chapter 7, Spar returns to the theme of the market-what it means and ways to regulate or control it. 12 Recognizing the common concern or desire for a healthy child and the interplay between business, government, markets, and morality, she concludes with a plea for government "to play a more active role in regulating the baby trade."
13 She has her sights on the United States, which she sees as granting the infertility industry "an extraordinary exception: one of the very few industries to operate with virtually no rules." 14 But the push toward cloning and fetal research, and our continual willingness "to buy, sell, and modify our children, generating substantial profits in the process," will eventually lead us to "a regulatory framework in which the business of babies can proceed."
15 Nary a word, however, on what the form or content of that regulation should be.
The seven chapters of the book vary in quality. Some of the facts are interesting, as in Chapter 2's list of the 20 IVF programs that perform the most cycles, 16 and her account of policy issues in Chapter 7.
17
Lowfrequency and nonexistent practices (surrogacy or cloning, respectively) each get a chapter, while there is nothing on embryo moral status and the way it 12 . She reminds us again that the "central contention of this book, however, is that there is a market for babies, a market that stretches across the globe and encompasses hundreds of thousands of people." SPAR, supra note 3, at 195. She then recognizes its differences from other markets; she claims it is less sensitive to supply and demand, cannot provide all the "goods" desired, lacks unambiguous property rights, and is subject to mischaracterization as charity. Id. at 195-96. However, Spar never explains why thinking of it in market terms is useful.
13. Id. at xviii. 14. Id. Given the regulations that do exist, see infra note 168, this statement is at best tendentious.
15. Id. at xix. The mention of fetal research is odd because debates about it do not easily link up with concerns about ARTs. Debates about embryonic stem cell research are about embryos, not fetuses.
16. Id. at 54. Spar's data is for 2002, and it is taken from data in CTRS. FOR 
DISEASE CONTROL & PREVENTION, U.S. DEP'T OF HEALTH & HUMAN SERVS., 2002 ASSISTED REPRODUCTIVE TECHNOLOGY SUCCESS RATES (2004)
. The CDC prepares its annual report of ART success rates based on data provided by the Society for Assisted Reproductive Technology (SART). SART maintains an active list of ART providers, and electronically collects data for each ART procedure started during the year. The collected data includes information related to the patient's medical history, the ART procedure used, and the results of the procedure. The reports are made available to the public through the CDC's website. See Ctrs. for Disease Control & Prevention, http://www.cdc.gov/ART/ARTReports.htm.
17. SPAR, supra note 3, at 195-233. [Vol. 85:665 has influenced so much of public policy in this field. 18 She mentions "fetal research" as a developing issue, 19 but says nothing about it, perhaps because it does not frequently occur and is not related to treating infertility as such. It is good to include a chapter on adoption, but the issues involved with adopting a born child, though sharing some commonalities with medical treatment of infertility, are too distinct to be useful. 20 Her account of embryo selection is generally good and up to date, 21 but adds nothing for anyone following that field. Chapter 7 is the best because it more systematically tries to present a framework for analysis. But this framework is too sketchy and comes too late to be of use for assessing accounts in previous chapters.
A major problem is that not until the last chapter does Spar tell us what she means by a market and why use of that term is helpful. For her there is a market because there is demand and supply, prices that link the two, and businesses that "sell their wares." 22 Although parents seek to acquire children all the time through sex and marriage, "[w]hat differs . . . is the mode of acquisition in the baby business; it is the entry of commerce into what many regard as an entirely noncommercial affair." 23 The problem is that Spar uses the term "market" and "business" in a very broad sense, indeed such a broad sense that the terms lose their ability to tell us something new. 24 Any exchange of anything for something can be thought of as a market or business. In fact, Spar is not literally saying that born babies are bought and sold or even that embryos are. Rather, she is simply calling attention to the idea of a market as a system of matching demand and supply, with money playing a role in facilitating the exchange of some of the components and paying the experts and other actors who arrange it. After pages lamenting the existence of a market, she waits until the last chapter to confront the market definition questions that should have been addressed in Chapter 19. SPAR, supra note 3, at xix. 20. Since the child is already born, the emphasis is on birth mother relinquishment, adoptive parent fitness, and legal status and filiation of the child. With ARTs, the concern is with getting a child in the first place, which is not guaranteed. While legal and ethical issues that arise in adoption are also relevant to ART, the differences may be more important. For a discussion of the connection, see JOHN A. ROBERTSON, CHILDREN OF CHOICE 142-44 (1994 But is this question so difficult? Since babies are not yet born, one is literally buying the prospect of a baby, not the baby itself. "Baby business" adds a sexy ring to the dryness of numbers, but paying people who provide the factors or services needed to conceive and bring children into the world is not the same as buying a baby that is already born. The techniques involved and social arrangements in which they are embedded may raise special problems, but it is imprecise and inaccurate to say that a sperm or egg donor or ART center is "selling babies." As many disappointed fertility patients know, obtaining gametes or embryos or even initiating pregnancy is no guarantee that they will take home a baby.
As a result, Spar conflates payment for a part with payment for the whole. Because payment or commerce is involved with some of the steps needed to enable a child to be born, it does not follow that there is commerce in exchange for the finished product. Payment for those steps may be needed to have a child, but so is payment for medical and obstetrical services that have become essential in developed countries for having babies. Once birth has occurred, parents buy a variety of services from pediatricians, day care workers, teachers, and others to have a healthy, well-developed child, but we rarely speak of "buying" a child's development. If we sometimes speak of the "business" of children's healthcare or daycare or education, that label itself adds few interesting questions beyond access. Given that we pay for prebirth medical and obstetrical services and postbirth medical care, rearing, and education, why should it be surprising or shocking that money is paid to IVF doctors, sperm and egg donors, gestational surrogates, adoption agencies, donors, and the brokers that facilitate those transactions? 26 25. SPAR, supra note 3, at 207. 26. The insightful essays by Prichard and co-authors Landes and Posner about a market in children address only born children and omit any discussion of embryos, gametes, or uteri. See Landes & Posner, supra note 24, at 323-24 (introducing the concept of baby markets, adoption, and foster homes but omitting any reference to the prebirth market); Prichard, supra note 24, at 341 (examining the use of "a market mechanism . . . for the adoption of newborn babies" without mention of the prebirth market). A market in reproductive factors may enable children to be produced, but it does not involve an existing person with rights, as is the case with adoption of born children. But the three authors' point about how paying money for adoptive children will induce a greater supply also holds for gametes and embryos. See Landes & Posner, supra note 24, at 325 ("At a higher price for babies . . . the costs of unwanted pregnancy would be lower while the (opportunity) costs to the natural mother of retaining her illegitimate child would rise."); Prichard, supra note 24, at 345 (stating that under a market mechanism, "one would anticipate an increase in the quantity of babies supplied in order to meet the demand" rewards are insufficient to prevent the "collapse" of the gamete donation system, policy makers should be prepared to consider "a system of limited payment"). Prichard's discussion of commodification and Spar argues that the difference "is the mode of acquisition in the baby business; it is the entry of commerce into what many regard as an entirely noncommercial affair."
27 But she presents no evidence that people really think that receiving technologically sophisticated services from doctors and others should be "an entirely noncommercial affair."
28 Parents have to pay for obstetricians, pediatricians, dentists, daycare centers, and teachers. Why should they not have to pay for fertility specialists to enable conception and pregnancy to occur? There is no more reason to have reproductive endocrinologists work for free than to expect obstetricians and pediatricians to work as altruistic volunteers.
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This is not to say that there are no unique problems and issues that arise in ART, gamete donation, and surrogacy. Such problems include: (1) ownership and control of embryos; (2) protection of couples, donors, and surrogates; and (3) determining parenting relationships. Sometimes issues of payment arise, as in whether egg and embryo donors should be compensated. But these are a series of local problems within different subareas that are not usefully linked by a global notion of "market" or "baby business." Resolving these local problems does not turn on developing a comprehensive approach that will integrate all the different avenues-IVF, donor sperm, adoptionthat substitute for one another or input to reproduction. Nor does adding catchy labels for modes of regulation-Spar's luxury, cocaine, kidney, and hip replacement models 30 -help us decide whether a laissez faire, prohibitory, or subsidized approach should be taken to particular aspects of assisted reproduction.
Spar seeks acclaim for making the obvious point that money is paid for many of the steps in treating infertility. But her big bang of discovery-that market transactions are occurring in helping infertile couples conceive-ends with a promarket whimper about the inevitability of "that idiosyncratic trade" and precious little elucidation about what to do next:
Drawing [policy] lines in the realm of reproduction will not be easy. It will entail an intense political debate across an intimate and often tragic landscape. But we must have this debate, and we must make these choices. We need to acknowledge the market that reproductive symbolic meanings is also relevant. Prichard, supra note 24, at 352 (discussing the moral ramifications of treating life as a commodity); see also infra notes 119-25 and accompanying text (discussing the sale of embryos). 27. SPAR, supra note 3, at 196. 28. Id. 29. Nor do we shrink from paying for cancer treatment, heart transplants, and other things to keep people alive, even when all cannot get the treatment. There are parallels, however, between not paying for organs and not paying for embryos. See infra note 119 and accompanying text.
30. The "Luxury Model" would treat ART like buying fine jewelry, a practice only for those who can pay. SPAR, supra note 3, at 217. The "Cocaine Model" would ban all ART and adoption or their subparts. Id. at 218. The "Kidney Model" would allow altruistic and nonpaid donation, but no payments to donors. Id. at 219. Finally, the "Hip Replacement Model" would regard fertility as a social good, which government and society should provide for all who need it. Id. at 220-23.
technologies have created and then figure out how to channel this market toward our own best interests. . . .
[O]nce we decide to approach the baby business as a market subject to regulation, we can begin to determine which pieces of this market should be treated like kidneys, which like heroin, and which like hip replacements. The remainder can stay as jewels.
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II. Thinking in Market Terms: Supply, Demand, and Competition Because ART is a big business, it would be interesting to have a Harvard Business School perspective on the nature of the industry, supply and demand factors, conditions of entry, competitive advantages, successful business plans, and the like. Spar gives us selected tidbits, especially in Chapters 2 and 3, but does not serve the full course meal we are led to expect. Rather than have the reader of this review leave the table hungry, I offer here a fuller look at some of the business and market-related issues that she might have profitably pursued. One set of issues involves demand side issues of who gets access. A second set of issues concerns factors affecting the supply of fertility services.
A. Demand Side Issues
On the demand side, important questions concern who wants ARTs and who is able to get them. The potential market is infertile couples and individuals who are infertile or who due to sexual orientation or other special factors are unable to have children. Yet, only a minority of infertile persons get ART services. In some cases, this has to do with personal preference, since there are physical and moral costs to using some of these techniques. In other cases, there are resource problems. Some countries treat ART and infertility-in Spar's terms-like a hip replacement, that is, as a needed medical service that the national health system should pay for. Others treat it like a luxury good available only to those who are able to purchase it.
One may legitimately ask whether such an investment to produce a child is worth it, and whether society should subsidize it. That inquiry would look at the costs and benefits of coverage, what it does to others in the health insurance pool, and whether it is worth subsidizing in a national health system. 32 If not covered, obtaining such children becomes a luxury good of sorts (Spar's luxury model). In the United States, few states mandate insurance coverage, and health insurance coverage for fertility services is rare. Except in Illinois, Maryland, and Massachusetts, ARTs are rationed by the ability to pay direct out-ofpocket charges. 33 Although infertility affects all economic groups, most people perceive access to basic healthcare as a more pressing problem. The 1992 Clinton health care plan, for example, specifically excluded IVF, 34 and no one now seriously argues that the financially strapped Medicaid system should cover ARTs. European countries, with their lower birth rates, have to face whether to give subsidies, or whether to create barriers on moral grounds, as in Italy. 35 In addition to access, an important demand side issue is the "captive" nature of some patients. For many women and couples, infertility is a source of enormous suffering. Some become desperate to conceive and seem willing to use any technology that has the slightest chance of working. 36 Patients may downplay the true risks and overinflate the likelihood of benefit, insist on additional procedures that have little likelihood of working, or be vulnerable to exploitation by profit-driven providers who overplay the efficacy of their procedures. 36. The 12%-15% success rate that some women face seems low. See CDC REPORT, supra note 1, at 23 (reporting that the live-birth rate of ART cycles implanting fresh nondonor eggs or embryos in women aged 40 to 41 were 12.6% and 15.5%, respectively). However, the medical care system provides second and third line cancer therapies that have that rate of success or lower, though they are more onerous and may not lengthen survival beyond a few months. Extending life, however, is seen as more pressing than treating infertility.
But there are built-in constraints here. 37 People will be more careful about incurring out-of-pocket costs for ART than if insurance pays for it, particularly given the rigors of the procedure. There is now a widespread network of support groups, and information about success rates of particular programs is a few mouse clicks away.
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Paying patients can be more discriminating in what they request and better equipped to question medical recommendations. Also, persons who opt for ART will probably be seen by board-certified reproductive endocrinologists, treated in laboratories with some degree of certification, and thus less likely to receive poor quality care. But mishaps occur in even the best regulated systems, and may occur more frequently where regulation is absent or only professionally driven.
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There are also demand side limits to adoption of the more exotic procedures that garner the lion's share of public attention and drive a good deal of the concern about commodification, such as cloning and genetic engineering. Most infertile persons are driven by the desire to have genetically or biologically related children for rearing. As treatments move further from coital conception and the chance to rear biologically related children, problems increase and demand drops. Safe and effective reproductive cloning is still far off, 40 but even if it worked, it is unlikely that there would be a great rush among fertile couples to use it, and only limited demand from the infertile. Nor will people quickly queue up for embryo screening if coital conception is likely to provide a healthy child. The ease and efficiency of new technologies might eventually change the situation, but learning the genomic secrets of complex traits and manipulating them in advance is still too distant a dream to worry us for at least another decade or two and perhaps more. A final demand side issue is the shift in social norms that supports demand for ART services by unmarried persons. One development is the greater willingness of single or unmarried persons to have and rear children. 41 The second is the growing acceptance of gay and lesbian rights, including the right to use assisted reproduction to have children and rear families. 42 Indeed, the fact that gays and lesbians have and rear children has been a major reason why some courts have been sympathetic to the cause of same-sex marriage. For example, a main factor driving the Massachusetts Supreme Judicial Court's recognition of same-sex marriage was the sense that the children of gays and lesbians should have the same social support and stability structures that the children of opposite-sex marriage have. As the court explained, it "cannot be rational . . . to penalize children by depriving them of State benefits because the State disapproves of their parents' sexual orientation." 43 The New York and Washington supreme courts, however, in closely divided opinions, found that the need to promote procreation by heterosexuals required the opposite result.
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Refusing to recognize same-sex marriage is not likely to stop the march toward gay reproduction, which may increasingly turn to assisted reproduction for help.
The demand for reproductive services from gays and lesbians raises a supply side problem for infertility professionals. The hallmark of professionalism has traditionally been the right to select one's own clients and to control the technical details of the services provided. 45 State and federal civil rights laws now limit professional choice over clients on the basis of race, sex, ethnicity, and disability, 46 with a few states and cities also banning discrimination on the basis of sexual orientation. 47 In states that have not added sexual orientation to the banned list, doctors are legally free to refuse to provide ART services to gays and lesbians. But professional organizations of fertility specialists have found that discrimination against single or married persons on the basis of sexual orientation is not ethically acceptable. 48 Although not legally enforceable as such, this means that a program or doctor should help a single woman or lesbian couple with donor gametes and IVF.
It also means that they should provide egg donation and surrogacy to single or coupled gay males, despite their religious or other beliefs about the desirability of parenting in those circumstances.
Notice how little attention this discussion has paid to the parenting capabilities of infertile couples and persons. This is not surprising given that no screening of parenting ability occurs in coital conception, which assisted reproduction tries to mimic. Some programs screen prospective parents by refusing to accept them as patients. Unless motivated by race, gender, or disability, they are free to reject patients who seem ill-equipped for parenting. 49 Even with donor gametes and surrogacy, however, there is little formal screening of whether the recipient of the donation or the hiring couple is a fit rearer. Some argue that there should be more screening, pointing to a case of child abuse by a single male who obtained a child through a surrogate (1) (1992) (declaring that the city's policy is "to foster and enforce to the fullest extent the protection by law of the rights of all of its inhabitants to equal opportunity to gainful employment, housing, credit and the use of City facilities and public accommodations without regard to . . . sexual orientation").
48. mother and concerns that others, such as pedophiles, might be able to exploit current regulatory gaps for illicit purposes. 50 Unless a born child is involved, however, the adoption-like screening of parental abilities is unlikely to occur.
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B. Supply Side Issues
There is an ample supply of qualified providers to meet the demand for services presented by paying patients in the United States and to varying extent by paying and subsidized patients in other countries (though there may be legal constraints on certain procedures). Success rates are steadily creeping upwards, and patients have easy access to comparative data.
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Laboratory accreditation and FDA-required tissue handling practices for donor gametes protect against infection. 53 If anything, there is less chance of harm to patients than in other areas of medicine, if only because fertility treatment is largely an elective procedure for otherwise healthy patients. 54 In the United States, reproductive services are an attractive option for some obstetrician-gynecologists. Patients are not as "sick" as other gynecological patients, e.g., those in gynecological oncology. Nor do fertility specialists have to get up in the middle of the night to deliver babies or worry about a malpractice claim every time a less-than-healthy baby is born. In 2005, there were at least 415 fertility clinics in the United States, suggesting that there are few barriers to entry in the market other than the success of other providers. 55 The biggest firms do the most business and have the highest success rates, but many small practices exist, and there is ample room for niche or boutique practices that specialize in subgroups of patients or services.
Spar takes us but a few short steps into this highly decentralized "industry." We do get a chart that lists the top twenty programs in terms of number of cycles, 56 but there is no attempt to tell us what explains the success of some and the failure of others. Favorable state insurance laws might explain the presence of Massachusetts, Maryland, and Illinois programs on the list, but not those from California, New Jersey, and New York. 57 Since she does not give us comparative pregnancy and take-home baby rates for these programs, we can't tell whether more successful programs draw more patients or whether other factors explain their higher activity. Indeed, many smaller, nonacademically affiliated programs have good success rates. 58 CDC-SART annual reports of clinic-specific success rates provide a wealth of information that could be mined for economic or business insight into infertility practice. 59 But Spar hasn't done the work. She does give lists of prices, but surprisingly does not mention one area in which price competition has emerged. Several programs, including the Shady Grove Fertility Center in Maryland, which innovated in this area, started a "shared risk" or money back guarantee program. For a set fee, the program would offer three cycles, and, if no baby was born, would refund the money. 60 It would be interesting to know whether such insurance programs have reduced costs for patients or otherwise have been a successful business strategy. Shady Grove Fertility Center is the third ranked IVF center in terms of procedures done, while the Genetics and IVF Institute in Fairfax, an early leader in egg donation, PGD, and sex selection, does many fewer. 61 One operates in a state with insurance coverage for IVF, Maryland, while the other state, Virginia, does not. But one also provides shared risk and the other does not. Nor does she say anything about the factors that lead to firm failure and closure, as nearly occurred in an academic IVF program at the University of Wisconsin at Madison. 62 The field, however, has had its share of hyped-up marketing of new techniques to attract customers, such as egg or ovarian tissue freezing, 56 . SPAR, supra note 3, at 54. 57. See supra notes 33-35 and accompanying text. 58. Eight of the top ten programs are free-standing, with no connection to a university or medical school. Spar thinks that connection is important but never provides data or analysis to support it. SPAR, supra note 3, at 49-55. screening embryos for good genes, and cloning. As in other areas of medicine, untested therapies are often first introduced as innovative therapy without the systematic evaluation needed to show that they work. The questions may rise in a new setting, but the questions are not new. 63 Nor have they received any greater attention than they have received in those other areas.
Other than the high cost of ART procedures, the greatest barrier to assisted reproduction in some countries are restrictive laws about what procedures may be done and who may receive them. Moral constraints, however, are less likely to affect basic IVF than procedures such as egg donation, embryo screening, treatment of unmarried and gay persons, and the like. Germany, for example, has laws highly protective of embryos, but reported in 2002 nearly 85,000 ART treatment cycles. 64 Yet, Germany does no egg donation or preimplantation genetic diagnosis. 65 Ireland and Slovenia appear to have few IVF centers, 66 but infertile couples can easily travel to Switzerland, Germany, or the United Kingdom for treatment. Reproductive tourism, however, is an option only for those who can pay.
C. The Market for Babies
Spar's focus on infertility as "the baby business" recalls the famous 1978 article by Landes and Posner, The Economics of the Baby Shortage.
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They looked at the shortage of babies for adoption and made an economic argument that women should be paid to give up babies for adoption. 68 Among the benefits would be to reduce the abortion rate.
69 Their hardheaded analysis touched off the debate over paying money for children and other contributions that have been a main current of bioethics for at least twenty-five years. The latest kerfuffle about paying woman who donate embryos to research testifies to its staying power. 71 In this case, Mary Beth Whitehead, the surrogate mother, fled with the baby fathered by and intended for the Sterns. 72 The courts eventually gave primary custody to the Sterns, with visitation rights to Whitehead. 73 Some states responded to concerns raised by cases like Baby M by regulating the compensation paid to surrogates similar to regulations in the adoption context. 74 The California Supreme Court introduced a bolt of clarity into the field with its favoring an intentionalist approach to rearing rights in a child born from an embryo made with the gametes of the infertile couple and gestated by another. 75 However, it has turned out that surrogacy is but a small part of the infertility industry, with only about 500 gestational surrogacy transfers every year (in a field where 75,000 IVF cycles are done annually). 76 In the 1990s, when egg donation took off, the ethics of paying women received very little of the attention that it had received a few years earlier in the surrogacy setting. But the same issues are at work, as discussed below.
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III. Six Current Controversies
The remainder of this Essay delves more deeply into market and commercial aspects of ART, trying to answer Spar's question of what defines the boundary of the market and commerce, and how that boundary is decided. The fact that money is paid and there is commerce of sorts is not in itself interesting. Medicine is rife with prices and markets. There are no free lunches and everyone has to make a living. It is more interesting to explore the problems markets create in particular areas. That calls for a series of more local investigations to identify conflicts and how they might be resolved. I investigate six areas: infrastructure, twinning, paying donors and surrogates, selection, embryo status, and regulation. null and void as contrary to public policy, while others regulate them, limiting the extent and form of compensation that can be offered, the class of women who may act as surrogates, or the circumstances in which surrogacy contracts will be entertained.").
75. See Johnson v. Calvert, 851 P.2d 776, 782 (Cal. 1993) ("We conclude that . . . she who intended to procreate the child-that is, she who intended to bring about the birth of a child that she intended to raise as her own-is the natural mother under California law.").
76. An estimated 500 children were born by gestational surrogacy in 1986, and in 2001 there were 571 recorded surrogate contracts in the United States. SPAR, supra note 3, at 82, 94.
77. See infra notes 103-25 and accompanying text. [Vol. 85:665
A. Market Infrastructure: The Need for Rules
An important requirement for market relations are clearly defined rules of property, contract, and exchange, which enable people to know what they are trading and what the consequences of carrying out agreements will be. Indeed, legal rules, like a highway system, are a subsidy that society provides to facilitate exchange. This is as true for exchanges of reproductive factors and services as for any other sector of the economy. But while the general background rules of property, tort, and contract apply to assisted reproduction, the novel context in which they arise do present particular kinds of legal uncertainty. An efficient system of reproductive technology needs an infrastructure of legal rules for how technology affects ownership and control of gametes and embryos and the rearing rights and duties in the offspring generated by ART.
Spar, to her credit, is aware of the general need for legal infrastructure for reproductive transactions and services. She talks about the need to "embed this market in an appropriate political and regulatory context . . . to produce the goods we want-happy, healthy children-without encouraging the obvious risks."
78 To make the market in babies work better, she favors a more explicit system of property rights, 79 meaning clearer rules for dispositional control over gametes and embryos, the contractual rights of donors and surrogates, and the rules for assigning social parentage in resulting children. 80 Spar, however, overlooks the extent to which such rules already exist or are in the process of development. The absence of an overarching legal code specifically for assisted reproduction does not mean that all rules are absent, nor that all questions be settled in advance. Indeed, if the business or market for reproduction is as robust as she claims, there is likely to be sufficient certainty to enable people to invest resources and time in providing and seeking services. With new technologies, the areas that need rules come to light only after experience has identified problems and proposed solutions. We may still be too early in the rule-development cycle for norms for all areas of reproductive technology to have emerged. Most are likely to fall under the domain of principles that apply from other areas of law and morality. Despite the lack in most jurisdictions of a legislative code for assisted reproduction, an infrastructure of legal rules for dispositional control over embryos and for assignment of parenting rights in offspring is largely in place. 82 Take, for example, ownership and control of embryos. It has long been clear that the gamete providers have joint dispositional authority over the embryo vis-à-vis the ART clinic, which functions as a bailee of the embryo, not an owner in its own right. 83 Thus, it is obligated to return the embryo to the couple, subject to whatever terms the parties agreed to as a condition of their providing gametes and producing embryos. If the clinic intentionally, negligently, or even non-negligently fails to provide it, it is subject to legal remedies. 84 The principle of joint dispositional control would also require the gamete providers to agree on disposition of embryos, for example, whether they are implanted in the woman, discarded, or donated for research or to another couple. The Boston case involving an embryo implantation in a woman without her ex-husband's consent that Spar mentions 85 is a direct application of this principle: the ART clinic should not have transferred X and Y's embryo to Y's uterus without the consent of each. A semblance of clarity has also developed for resolution of disputes during divorces over embryos-the most litigated area in the law of IVF. , is less important than the fact that a legally cognizable loss to the "owners" of the embryo has occurred. Here the question is whether a state that defines a fertilized egg as a subject for murder will have to recognize it as a person under its wrongful death statute. But even if it does, there will still be uncertainty as to what damages to award for the loss of an early embryo that may never have implanted or come to term. The aliquot cost of creating the lost embryo is one measure. But those damages may be insufficient to support a lawsuit for recovery.
85. SPAR, supra note 3, at 198. The other area in need of legal infrastructure is the rules assigning rights and duties in offspring born with the help of donated gametes or surrogates. Although the rules were only hazily limned at the start of the field in the 1980s, the law for assigning parentage in cases of sperm donation to a married couple were already in place. The sperm donation model of intent and agreement, while not perfectly applied in all cases, has provided enough legal certainty about future parentage to enable people to go forward with the use of donor sperm for unmarried persons and egg and embryo donation for married and unmarried couples. 87 As disputes arise, the law will be further clarified. The latest series of cases from California shows that we are well on our way toward recognition of the principle of contract between donors and recipients as a hallmark-though not always a guarantee-of resulting parenting relations. 88 Spar also says nothing about the moral dilemma that the need for legal infrastructure presents to those loathe to accept ART in the first place. Creating infrastructure signals approval, legitimizes the practice, and encourages expansion by reducing the planning costs of those engaging in it. Yet, developing those rules itself has opportunity costs, which could be significant for the legislators, judges, and parties who enact policy. 89 On the other hand, refusing to provide legal infrastructure may increase litigation and uncertainty, and end up harming children caught in battles over rearing rights and duties. 90 With these competing concerns, it is not surprising that so few states and countries have a comprehensive code in place. In the meantime, a common law of responses will fill the gap and occasionally spur legislative clarification or codification. A set of legal rules specifically App drafted for ART has not been a barrier to full-throated development of the field.
B. Treatment Externalities: Anomalies, Twinning, and Novel Families
Reproduction is generally viewed as an important individual and social good. 91 A main focus is on the personal importance of reproduction to the individuals involved, but attention to the social importance of reproduction is not far behind. Reproduction is necessary to replenish the workforce and support previous generations of workers.
92 While high birth rates put pressure on natural resources, low birth rates impair society in other ways. Thus, unsurprisingly, there is generally wide social support for ARTs. Yet, some European countries with declining birth rates have policies that undermine or discourage a wider use of ART.
93
A special problem posed by infertility treatments are the hidden externalities that may be created. Although there is general social support for childless couples reproducing, technologically-assisted reproduction might generate greater health care costs and other social costs. 94 One externality is the doubled risk that IVF offspring will have lower birth weight or congenital anomalies.
95 If this is true, then prospective patients need to be informed so they can make a more knowledgeable choice. Since many will still find the risk worth taking, their private action could lead to higher medical and social costs than coital reproduction ordinarily does. Without more data and study one cannot be sure that the differences are great enough to charge parents 93. It also makes it quite odd that Italy, with a falling birthrate, would be so unsupportive of basic IVF. It will discourage some people from reproducing at all or force those who can afford it to seek services outside of Italy. See John A. Robertson with social irresponsibility in using IVF, much less warrant public policies to discourage its uses. It is unlikely that ARTs would be banned or taxed because of these externalities. It does, however, provide a further reason, at a time of strained health care budgets, not to subsidize them through insurance.
A second source of externalities from ART is the higher rate of multiple births. About a third of all IVF births involve multiples, most of them twins. 96 The rate of higher order multiples has been reduced in the United States and other countries through professional guidelines. 97 But twinning remains a major problem for children, families, and the medical care system. 98 A singleton birth is the most desirable situation for the health of the mother and offspring, and medical and social costs generally. Twins have a higher rate of premature birth, time spent in ICUs, and more medical and social problems. 99 Yet, infertile patients often welcome twins. Lowering the rate of twins, however, is a difficult problem.
One way to reduce the rate of IVF twins would be to transfer no more than one embryo to the uterus at a time. Sweden and Belgium have used insurance incentives to encourage patients to accept single-embryo transfer, 100 and some programs have had great success with it. 101 But the issue is a tricky one, especially in the United States, where twins are generally seen as a good outcome. In the American pay-as-you-go funding system, few levers exist to dampen patient enthusiasm for two babies at the price of one, especially since insurance coverage kicks in once the twins are born. ART patients are happier, which may affect the program's reputation, if two children are born rather than one.
The trade-off, however, is not between two children or none, but between the greater health risk of twins and the additional frozen embryo cycle that a single-embryo transfer policy will require for an equivalent success rate. In the best patient groups (women under 35), European data shows that the chance for a singleton birth after a fresh and frozen transfer is 96. Robertson as great as if two embryos are transferred in a fresh cycle, with its higher risk of twins. 102 A rational health care system would push toward single-embryo transfer in these groups when there are enough embryos to freeze. But the patient does not internalize all the costs of twins, so there is little incentive to build a system in which patients in good-outcome groups would be required or encouraged to undergo one fresh and one frozen cycle (instead of one fresh cycle with two embryos) in order to minimize the rate of twinning.
Professional and insurance guidelines and patient education may be more apt policy levers here than legislative action. But even better education of patients may be limited in what it can do. The doctors involved have an interest in satisfying patients. If patients insist on transferring at least two embryos, it will be hard for doctors to say no. Nor will they push too hard to inform them, e.g., emphasizing the negative nature of twins from a social policy viewpoint when other features of that system smile on the birth of twins.
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Some persons might also argue that the anomalous family situations that arise with interchanges of gametes and gestation might generate social and emotional complexities that operate as a social externality. Medical, educational, and legal systems must expend time on a new set of issues. Children will face new sets of parenting problems. Despite their great resiliency, they might not do as well in such situations, which could generate social costs for others. The question of "social externality" requires more discussion elsewhere. Suffice it to say that the application of the concept of "social" externality in the ART setting may be too fine-grained and elusive to merit special attention in policy-making.
C. Paying for Gametes and Gestation
Many doctors make a prosperous living off treating infertility, but this appears to be of lesser moral concern than is the practice of paying gamete donors and surrogates for their services in helping an individual or couple to reproduce. Despite her bathetic hand-wringing about the "baby business" and many references to surrogacy and egg donation, Spar does not give a systematic account of the role of payments for donors and surrogates, much less an analysis of whether uncompensated donations-her kidney modelwould work as well as a free market approach.
The United States follows a market approach, subject to professional guidelines. 104 Abroad, paid gamete donation is often banned, as in the United 102. Anderson et al., supra note 64, at 1686. 103. Although Spar recognizes the general problem of costs, she devotes but a single paragraph to the topic of multiples and shows no awareness of the progress made in lowering the incidence of triplets and higher-order multiples through professional self-regulation. Nor does she mention the controversy over single-embryo transfer. See SPAR, supra note 3, at 229. 106 In those countries, few women in need of egg donation (those with premature menopause or in older age groups) will be able to have children because of the rarity of purely altruistic egg donors.
Despite the negative reaction elsewhere to paying women for egg donation, in the United States it is widely accepted that egg donors are and should be paid for their services in providing eggs for reproduction. Professional guidelines stress that the payments are for services, not for the eggs themselves, and suggest limits to prevent undue influence. 107 It appears that egg donors are motivated both by the desire to help infertile persons as well as receive compensation for their time and effort. Few women appear to have been injured or harmed by paid donation, and many older women or couples have been able to have biologically or genetically related offspring as a result. Careful attention to informing the donor of potential medical, legal, and psychological risks, and treating adverse events in the few cases in which they occur, remain essential to an ethical system of egg donation, whether paid or unpaid. Advertisements for $50,000 or more for "blond, high IQ, and Ivy League" donors have generated much negative publicity, 108 but such practices, if they in fact exist to any significant extent, appear to be a tiny part of donor egg practices in the United States. They can hardly be cited as an example of exploitation of the poor and vulnerable.
The issue of paying for egg donations has taken on renewed attention in the context of the embryonic stem cell (ESC) and nuclear transfer cloning debate. As the field develops, a major policy issue is whether women who 107. Thus, they should be paid the same amount regardless of the number or quality of the eggs retrieved. To prevent "undue inducement," ASRM guidelines currently limit payments to $10,000, though most paid egg donations for infertility appear to be in the $3,000-$5,000 range. Ethics Comm., supra note 104, at 216, 219. State and federal laws against paying for organs are unclear about whether gametes are included, but no efforts have been made to prosecute those who pay donors. See, e.g., National Organ Transplant Act § 301(c)(1), 42 U.S.C. § 274e(c)(1) (2000) (defining "human organ" as human and/or fetal "kidney, liver, heart, lung, pancreas, bone marrow, cornea, eye, bone, and skin or any subpart thereof and any other human organ"); see also provide eggs for ESC research and therapy should be compensated for their time and trouble in addition to compensation for out of pocket expenses.
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The only realistic prospect for obtaining sufficient eggs to meet research and therapeutic needs for the foreseeable future is from live donors (the use of cadaveric or fetal ovaries will require more knowledge of in vitro maturation of eggs than now exists). Some altruistic donors might be available, particularly from relatives of persons with diseases who might be treated with ESC derived therapies, but it is unrealistic to think that such donations will satisfy the demand for creating embryos for ESC research and therapy.
Given that the system of paid egg donation for treating infertility has worked reasonably well in the United States, the idea of compensating women for the time and effort involved in psychological and physical screening, hormonal stimulation, monitoring, retrieval, and the other steps involved in providing eggs for ESC research has strong appeal. Compensating women for donating eggs for ESC research is not only fair, but also consistent with the deeply embedded practice of paying subjects in biomedical research. Payments to research subjects have long been considered legitimate in the United States as long as it does not constitute an undue inducement.
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As recent scholarly analysis has shown, if the risks and benefits of the research to the patient or others are positive, payment alone to an otherwise competent and informed subject will not be "undue."
111 Nor is compensation "coercive" merely because it provides an incentive to persons to donate.
Despite the likely need to pay women for their efforts to provide eggs for ESC research and therapy, the National Academy of Sciences (NAS) in its 2005 "Guidelines for Human Embryonic Stem Cell Research" took the position that no payments should be provided to egg donors other than 109. See Lee Romney, New Battle Lines Are Drawn Over Egg Donation, L.A. TIMES, Sept. 13, 2006, at A27 (discussing a "spirited disagreement" as to whether women should be paid, rather than merely reimbursed expenses, for donating eggs for research). This issue has surfaced as a result of the ability to culture ESCs in the laboratory and the development of nuclear transfer techniques. While most human ESC research has occurred on leftover embryos, most observers expect that new lines will have to be created with donor eggs in order to obtain ESCs with sufficient genetic diversity to study many diseases and avoid immune reactions in future therapeutic applications. reimbursement of direct expenses.
112 It listed the arguments on each side of the issue, but gave no analysis of why the position against payment was stronger than the position for it. It did note, however, that "this policy should be regularly reviewed and reconsidered as the field matures and the experiences under other policies can be evaluated."
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In the meantime, two states actively involved in ESC researchCalifornia and Massachusetts-have banned paying donors of eggs for research except for the expenses of donation.
114 California has taken the position that expenses are limited to out of pocket expenses, 115 while Massachusetts has not yet defined "expenses."
Two recent developments suggest that the policy process may be "working itself pure" to permit payment as well. The first is the publication of guidelines by the American College of Obstetricians and Gynecologists (ACOG) approving of payment for services to donors of eggs for ESC research. 116 The second are the ethical guidelines set by the International Society for Stem Cell Research (ISSCR), the professional organization of ESC researchers. Rather than ban payment altogether, it leaves it up to each host country.
117 That won't help within a particular country, but it avoids setting an international standard against payment that might have developed 113. Id. at 87. It may be that the NAS's recommendation was nothing more than a pragmatic holding action that will allow ESC research to take place without further stirring the ethical controversy that now surrounds the use of human embryos in ESC research and therapy. Such pragmatic compromises, however, may have long-run costs that could outweigh their shortrun advantages. American research centers and the institutional and ethical boards that oversee ESC research may assume that paid donations are ethically verboten even if legal, as they are in nearly every state. Scientific organizations and countries across the globe that are unfamiliar with the workability of paid egg donation for infertility in the United States may also take the NAS guidelines as a final truth, ignore the highly tentative and unargued reasoning for its position, and entrench a policy against payment for years to come. after the Hwang fraud in South Korea, which involved researchers creating ESCs from eggs obtained by fraud or coercion.
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In my view, there are serious problems of efficiency and fairness with a kidney model of nonpayment for egg donation for infertility treatment or research. Bans on payments make it harder to get gametes and are not justified given the time and efforts of the donors. The arguments in favor of a ban would have to be the risk of coercion and undue influence in payment or a moral sense that any payment is per se wrong. If paid donation is acceptable for treating infertile women and recruiting subjects for biomedical research, then it should be acceptable for recruiting donors to provide eggs for ESC research as well. The key to protecting donors is careful practice and fully informed consent, not bans on compensating women who commit significant time and effort to providing eggs for ESC research.
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The same analysis would apply to payments for embryos and gestational surrogacy, but I limit myself here to a discussion of paying for embryos. This issue was recently raised by reports that a "made-to-order" embryo bank had opened in San Antonio, Texas.
120 Unaffiliated with any medical center, the program purports to make embryos for couples from a catalogue of sperm and egg donors. 121 In some cases, those seeking embryos can "buy readymade embryos matched to their specific requirements-even down to choosing what eye and hair colour they would like their child to have. . . . 119. The thrust of the argument presented here is that payment should be permitted for kidneys as well, but that topic is beyond the scope of this Essay. Paying for eggs is distinguishable from paying for kidneys because of the lesser physical burdens of ovarian stimulation and transvaginal needle aspiration of eggs, and the greater importance of a kidney to the body. Also, the need for healthy eggs will make it less likely that poor women will be the main suppliers of the market for eggs. 121. See Saunders, supra note 120; Wheldon, supra note 120. 122. Wheldon, supra note 120.
Texas Law Review [Vol. 85:665 attractive business model: it requires the development and maintenance of inventory for an unknown set of demanders. A just-in-time supply chain, with the described center acting as a broker for those who need embryos to reproduce, is more likely.
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While this overhyped venture has sparked much negative comment, there remains the question of why one should be especially concerned about it. In fact, there is likely to be little demand for it. Cases of simultaneous gametic insufficiency with ability to gestate constitute a very narrow subset of infertility patients. 124 Couples in that category might prefer two separate egg and sperm donations over the medical and social complications of leftover embryos from infertile couples. Since it is logical and reasonable to allow some selection in obtaining sperm and eggs, the fact that they are chosen together and then combined in vitro before transfer should not in itself be a problem.
Aside from the sirenic horror of "selling" embryos, the idea of brokering arrangements between egg and sperm donors and recipients makes sense. Adoption agencies are brokerage agencies. So are the sperm banks that procure sperm and distribute it to recipients and the individuals who match surrogates and couples or egg donors and couples.
125 Doctors will be needed to stimulate and retrieve eggs and transfer resulting embryos into a recipient, thus creating fiduciary duties to protect donors and recipients. Duties to offspring are less clear, but professional guidelines and ethical duties require some attention to whether the recipient has the requisite childrearing abilities.
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The brouhaha about a paid embryo bank should fade away once its brokerage role is clarified and the line between paying donors for their services, rather than for their gametes or the resulting embryos, is made clear. The latter line, of course, is a symbolic one, but that in itself is not sufficient to disqualify it. If we are comfortable with paying donors but not with buying and selling embryos for therapy or research, it is easy enough to maintain that line, just as we do in organ donation.
D. The Market for Selection
An important feature of IVF is that it opens the preimplantation embryo to the medical gaze and hence to screening, selection, and eventually 123. Embryo banks might, however, develop as a way of facilitating the disposition of excess embryos, and in the future could constitute a supply source of embryos both for infertile couples and researchers.
124. Cf. CDC REPORT, supra note 1, at 14 fig.2 manipulation, resulting ultimately in greater eugenic selection of offspring. In addition to morphology, embryos can be screened for chromosomal anomalies and genetic characteristics. Only healthy embryos or those having particular chromosomal or genetic make-ups would then be transferred to the uterus. Spar notes some of these possibilities, and then argues that "these technological prospects will lead . . . to a market," meaning presumably that prospective couples will demand embryo screening and reproductive providers will provide it for a price.
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It is unclear whether Spar is concerned about screening techniques themselves or the fact that money will be paid to obtain them. Instead of clarifying that point, she gives us a whirlwind tour of the history of breeding, Francis Galton, the rise of eugenics, sterilization of the retarded, and Nazi uses of sterilization.
128 She then shifts to discovery of the structure of DNA and prenatal testing of fetuses through amniocentesis and then ultrasound.
129 At this point, she describes the early development of preimplantation genetic diagnosis (PGD) for cystic fibrosis, and its current extensions to having children to serve as matched tissue donors for existing children and, to some extent, for nonmedical gender selection.
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By the end of her account, even Spar is convinced that the fear that embryo screening will lead to a market in genetically engineered children available only to the wealthy is overblown. 131 She recognizes that wanting a healthy child is natural, and that we already have a well-established system of prenatal screening for many anomalies. 132 With a family history of genetic disease, one can also screen prospective mates to see if they are carriers of genetic traits harmful to offspring. If so, the parents can avoid conception, seek donor gametes or adoption, or become pregnant and then screen the fetus to see if it is positive for the condition, in which case termination can be considered.
Embryo screening will allow some of that screening to occur on embryos prior to pregnancy. But getting embryos for screening is costly and intrusive, and will not occur unless there is a reasonable pay-off to the couple. Perhaps infertile couples already going through IVF will want it, but only a small minority of otherwise fertile persons will eschew coital conception and undergo out-of-pocket IVF just so they will be able to select embryos for implantation. The most likely subgroup to do so are those at 127. SPAR, supra note 3, at 99. The implication may be that there will be competition among providers as well. high risk for a genetically affected child, those with an existing sick child who needs a matched cord blood or tissue donation, those with hereditary cancer, and perhaps those interested in nonmedical gender selection. Embryo screening for other traits is unlikely for at least a decade or more, simply because of the complex matrix of genes and environment necessary to control for other desirable traits.
The market for selection is thus likely to be quite limited, even for couples otherwise going through IVF.
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Some programs will carve out expertise here, and technical progress may lead to comparative genetic hybridization and other techniques that will allow many more chromosomes to be viewed at a time. Most IVF programs are likely to contract out the screening to more expert firms, as already is occurring.
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As with other areas of reproductive innovation, an important policy question is whether any regulation is needed here, and if it is, will it be the result of professional guidelines or governmental action. 135 In the highly decentralized U.S. system, state or federal regulation of the acceptable purposes or uses of PGD are likely to be rare. If it occurred, such attempts at regulation might run into constitutional problems. 136 We must content ourselves with professional self-regulation with all its gaps and weaknesses. The American Society for Reproductive Medicine, for example, has been unable to clarify whether PGD for gender variety is acceptable, even though it has spoken in favor of sperm sorting for family balancing. 137 As a result, several member programs are conducting or advertising programs of nonmedical sex selection, including two by former presidents of the association. 598 (1999) , available at http://www.asrm.org/ Media/Ethics/Sex_Selection.pdf (concluding that, while "legal prohibition" is not warranted for nonmedical sex selection, "the cumulative weight of the arguments against nonmedically motivated sex selection gives cause for serious ethical caution").
138. For example, the Steinberg program advertises that it will provide nonmedical sex selection by PGD, seemingly going against the consensus in the field that nonmedical sex selection, if it occurs at all, should occur only for gender variety or family balancing and not for the first child. SPAR, supra note 3, at 122; Baruch et al., supra note 133, at 5.
139. See Human Fertilisation & Embryology Act, 1990, c. 37, (Eng.) (granting licensing authority over new clinics and procedures in the United Kingdom to the HFEA). See generally could require approval of new uses of PGD, such as to enable a family to have a child to serve as a donor to an existing child, to screen for cancer susceptibility genes, or for family balancing sex selection. The HFEA has approved PGD for chromosomal and genetic abnormalities, 140 but has an inconsistent history with other uses. Nonmedical gender selection, even for gender variety, is prohibited. 141 Initially, it approved PGD to ensure that a child will be a good tissue match for an existing child only if the screened embryos were also at risk for the condition of the existing child, thus leaving parents of a child suffering from noninheritable disease with no recourse.
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But the distinction between inherited and sporadic disease was too thin to carry moral weight, and the HFEA relented, allowing PGD for tissue matching for any disease, regardless of whether the embryo screened was also at risk for it.
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The HFEA has now gone even further and approved PGD to select out embryos that carry genes that make them more susceptible to cancer, even though the risk of cancer does not arise until adulthood.
144 This is a significant step beyond using PGD to screen out children with serious congenital anomalies or even high penetrance late-onset diseases such as Huntington's Disease because there is no certainty that the disease will develop even later in life. But, because it is a medical indication, it fits within the medical model and is more easily accepted than is selection for nonmedical reasons. 145 In the end, the prospect of embryo screening for more precise prenatal selection raises interesting questions about parental rights to select offspring traits and what that does to love for children, societal norms, and understanding of parentage. Leon Kass, Michael Sandel, and others object that any form of selection treats the child as a thing and denies its "giftedness." 146 But the idea of wanting to have healthy children is strong, and the arguments for blocking such practices are weak. A cocaine model of regulation for PGD is unlikely to emerge in the United States. 147 Regardless of how one answers the normative questions, the undeveloped state of technical and genomic knowledge will also forestall regulation. We simply do not know enough about the genomics of desirable traits to subject them to embryo screening in a way that would attract people not otherwise undergoing IVF. Nor do we know how to do safe and effective reproductive cloning or most of the other procedures that raise the greatest ethical hackles. 148 Even if we did, demand for those procedures would still be limited because of the cost and trouble involved.
E. Culture of Life Politics and the Market for ARTs
Spar is well aware that ethics and politics influence markets, but she says almost nothing about controversies over the moral status of the embryo and the noisy role that the "culture of life" has played in recent ART controversies. 149 Indeed, that influence may be much less than one would have expected from the high visibility of culture of life partisans in electoral politics, particularly in the abortion, emergency contraception, and ESC funding debates. Assisted reproduction often involves creating, transferring, freezing, or discarding embryos, necessarily implicating right to life issues that are contested so bitterly in the abortion and ESC setting.
The Warnock Committee in the United Kingdom and the American Fertility Society 150 in the United States took the position that the embryo was not a legal person or entity with interests, but nevertheless deserved special respect, if only on symbolic grounds. 151 As long as creation and use of embryos was for a legitimate purpose, such as medical research or treating infertility, it was acceptable to create, transfer, discard, or donate for research or infertility treatment. 152 This is the ethical or normative position that supports the legal regime of gamete source dispositional control of embryos that now undergirds assisted reproduction. 153 Some countries take a much more restrictive view of embryo status, most notably Germany and Italy. 154 They each require that all embryos be transferred to the uterus, that only a limited number be created, that no freezing or research occur, etc. 155 While Germany's position dates back to 1990, 156 the very conservative Italian position was enacted in 2004 and withstood a referendum to repeal it. 157 While no doubt a reflection of the importance of the Vatican in Italian politics, the enactment of the Italian law and the failure to reverse it by referendum show the strength of the right to life views in contemporary life.
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The most recent manifestation of the culture of life's strength in the United States has been in the ESC research debate that has roiled American politics for several years. Because ESCs are derived from early embryos, the question of whether it is ethical to destroy embryos for research or therapy poses a major barrier for some persons. In the United States, the issue has focused on federal funding, not prohibitions per se, and led to President Bush's first veto, when he refused to sign a law that would have reversed his administratively imposed ban on federal funding of ESC research.
159 But [Vol. 85:665 there is no federal law against discarding embryos or using nonfederally funded embryos for research. Nor does any state explicitly ban the discard of embryos, though a few come close. 160 An interesting facet of the ESC debate is how it has brought questions about the moral status of embryos into the public eye when for years embryos have been created and discarded in the course of infertility treatment without much public concern. Indeed, a main argument of those in favor of federal funding of ESC research is that the embryos in question will be discarded anyway. For them, embryos are too rudimentary in development to have interests that can be harmed by research on them. Rather than simply wash them down a drain, they argue that it is better that they be used productively in research.
Logically, right to lifers opposed to ESC research should also focus their attention on IVF clinics and their practices in creating embryos. If they are appalled that human lives are being destroyed for ESC research, they should be equally incensed by the great number of embryos created during IVF treatment, the number stored, discarded, etc. It certainly would be logical for them to demand that only a few embryos be created and all embryos placed in the uterus, as is the case in Germany and Italy. 161 Yet, surprisingly, there has been no serious effort by right to life groups to focus attention on IVF clinical practices, despite taunts by ESC funding proponents about their inconsistency in focusing on ESC research but not the assisted reproduction practices that create embryos in the first place. More careful attention at an earlier stage of the process could lead to fewer embryos being created for eventual destruction.
Politically, it would be a hard sell. It is hard to prevent those who are trying to have a baby from doing so most effectively, e.g., by telling them that only three eggs can be fertilized. This leads to a waste of eggs, the need for repeat cycles, and more costs and burdens to couples and the medical care system. Few persons think that the moral problem is so serious. This is true even at a time when thirty-six states have now made causing the death in utero of a fetus (and in some cases an embryo) a felony equivalent to homicide. 162 160. For example, Louisiana seems to come very close. See LA. REV. STAT. ANN. § § 9:122, 9:129 (2000) (stipulating that a human embryo in vitro is "solely for the support and contribution of the complete development of human in utero implantation" and shall not be "farmed or cultured solely for research purposes" nor be "intentionally destroyed"). IVF clinics in that state have not challenged the law.
161. Germany has finessed the issue by not including pronuclear embryos as embryos. Only at syngamy-emergence of a new genome at twenty hours after fertilization-does an embryo exist. The fertilized egg prior to syngamy can thus be frozen and discarded. See Robertson Continued growth of the power of the culture of life forces could lead to more restrictive IVF policies. But these are unlikely to dampen demand for ART services. Indeed, there may be some technical slack in the system, so that fewer embryos could be created and fewer discarded without impairing success rates or noticeably increasing costs to paying couples. Also, national guidelines that seem highly restrictive on the surface may not be so in practice. Germany, for example, protects embryos against discard or research but defines an embryo as existing only after syngamy, when the twenty-three chromosomes provided by each parent fuse into a new diploid genome, at roughly twenty hours after fertilization. 163 That enables German doctors and embryologists to freeze fertilized eggs at the pronuclear stage just prior to syngamy, 164 and achieve quite respectable success rates with thawed pronuclear embryos. 165 Italian law has not yet clarified its new law on this point.
A constitutional challenge would surely arise in the United States if a replica of the Italian law-a right-to-lifer's dream statute-were enacted. Infertile couples could attack the law as interfering with their constitutional right to procreate because it reduced the efficacy of an IVF cycle and increased the chance of having to undergo additional cycles. Such a case would force the courts to deal with the meaning of the right to procreate in the case of infertility and the kinds of burdens that state policies could impose on techniques sought by infertile couples or individuals to treat it. The lack of political will to impose such restrictions suggests, however, that judicial grappling with the issue is not in the offing. Given the importance of symbolic battles in the culture of life wars and the national focus that federal funding provides, this neglect of state ART restriction should not be surprising.
Culture of life forces may in future election cycles lose some of their political clout, but a less stringent application of their moral position has wide support. The respect due to embryos and the earliest stages of human life will continue to be a factor in future debates and policy-making. It is one of the factors that needs to be balanced in arriving at acceptable public policies for the genomic and reproductive innovations of the future.
F. The Vanishing But Not Extinct Need for Regulation
It has been a standard refrain in discussions of ART to bemoan the lack of regulation, and even call for a centralized system of regulatory control as occurs in the United Kingdom through the HFEA. 166 Spar, for example, states that there is no regulation of the ART field at all and seems to imply that more is needed. As usual, she does not tell us what form that regulation should take. In fact, a great deal of legal and professional self-regulation already exists. In addition to background tort, contract, and property doctrines and medical licensing laws, at least one state has laboratory and other regulations for ART. 167 If gametes, embryos, stem cells, or tissue from others are involved, the lab must meet FDA requirements. 168 There are also clinicspecific reporting requirements to the Centers for Disease Control. 169 None of these are perfect.
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Gaps exist, but there are many avenues of information, control, and market discipline by patients and others. The problem is less with regulation than with particular issues of regulation, many of them having to do with moral conflicts over the status of embryos, eugenics, and family affiliation law.
An unusual indicator of the absence of major regulatory problems with ARTs was the difficulty that the conservative President's Council on Bioethics (PCB), under the direction of Dr. Leon Kass, a noted bioethicist and long-time opponent of reproductive technology, had in finding problems or ways to improve the delivery of ART services. After two years of study, it issued a report in 2004, Reproduction & Responsibility: The Regulation of New Biotechnologies. 171 That report made some useful suggestions for increasing monitoring and information about these practices, but found none of the glaring problems said to exist in this "wild west" industry. 172 We can take the PCB's report as a benchmark for the state of the field and the lack of a compelling case for more extensive regulation. It found that much more research is needed before one can determine whether major 167. See Baruch et al., supra note 133, at 7 (noting that "New York has developed standards for laboratories that include oversight of genetic tests associated with" IVF).
168. Take the regulation of gamete donation that has occurred. The situation is hardly that of a business operating, according to Art Caplan, director for the Center of Bioethics at the University of Pennsylvania, as "pretty much a wild, wild west of the marketplace. changes in current practices and regulatory institutions are justified. 173 Like many other commissions, it recommended that the federal government and relevant professional societies gather more information about present practices and their effects. 174 These included such unglamorous steps as greater efficiency in reporting efficacy data, standardized consent forms, statistics on novel procedures like ICSI and PGD, and monitoring of the frequency of new practices, such as PGD and gamete sorting. 175 It also wanted more studies of the long-term effect of ARTs on offspring. 176 Recognizing that self-regulation plays a key role, it suggested a need for improving the enforcement of professional guidelines and for better methods for moving experimental procedures into clinical practice.
177 Surprisingly, although it discussed commercial issues, it did not recommend against a market for reproductive services or for paying gamete donors and surrogates. 178 None of these recommendations are surprising or revolutionary. They are marginal improvements to a market-driven system that will continue to be so. They are also a reminder that calling assisted reproduction "the baby business" paints with too broad a brush to be meaningful. As we have seen, there are many "baby businesses," involving paid exchanges for some component of the complex of activities and factors brought together to make a child possible. The fact that doctors must be paid, and not everyone can afford it, is not surprising, much less shocking. Despite its moral-driven scrutiny of the field, the PCB ended up more concerned with protecting "the dignity of human reproduction" by banning animal-human gestation, chimeras, and the production of fetuses to obtain stem cells than with IVF or the use of donor genetics. 179 
IV. Conclusion
This survey of the reproductive landscape engages several of the questions that Spar raises but never answers. Whether there is a reproductive market or "baby business" that needs special attention is itself contestable. But, if there is one, its boundary is unclear and variable, and shifts with the procedure in question, needs of infertile couples, societal standards of health and safety, technological developments, and concerns about protecting early human life and children. In a setting with so many cross-cutting issues, it would be unrealistic to expect otherwise.
In market-driven, largely laissez faire systems such as the United States, the people who decide those questions are those directly involved with offering and using these procedures-those who want them to overcome the obstacles to coital reproduction that fate has dealt them and the doctors who specialize in making them available. If the product of their joint decisions strays too far from societal norms, demand will falter or legislatures and courts will restrain them. More frequent slippage between practices and norms will accelerate the articulation of professional and societal guidelines.
In the end, the rules that govern "the most intimate of decisions" will be the same rules, turned to a more narrow focus, that we apply to other activities involving medicine, people, and children and the privacy and autonomy that characterizes it. The world of reproductive technology raises many local or specialized problems, but they are not fruitfully encompassed or clarified by calling them collectively a "business" or "industry." They are that, but they are many more things as well. In coming to terms with reproductive technologies, the business side may not be of foremost importance. 
